Thursday, June 26, 2008: Short Courses
An additional fee is required to attend all short courses.
8:30 am - 5:00 pm
Short Course #2: Overview of Monoclonal Antibody Immunoconjugates in Cancer Therapy
An additional fee is required to attend all short courses.
Several approaches have been used in the treatment of cancer, including radiation therapy, cytotoxics and cytokines. Treatment should be aggressively as possible to destroy the tumor but in doing so often leads to severe side effects and therefore many promising therapeutics cannot be administered systemically. Similarly many cytokines function physiologically in a para- or autocrine fashion at high concentration to have effects. One approach that is currently being investigated to concentrate the effects of these various agents at the tumor site is via conjugation to tumor specific antibodies. This short course will outline analytical issues in the measurement of these molecules in serum as well as preclinical and clinical development issues for antibody-drug conjugates and fusion proteins. Immunocongates will cover the following types of molecules; antibody-drug conjugates; immunotoxins; antibody-directed enzyme prodrugs; antibody cytokine fusion proteins; and bispecific double antibodies.
Moderators
Mark C. Peterson, Ph.D.
Amgen Inc.
Steven W. Martin, Ph.D.
Pfizer Inc.
Antibody-directed Enzyme Prodrug Therapy: Preclinical and Clinical Development with an Engineered Fusion Protein
Richard H. Begent, Ph.D., M.D.
Royal Free and University College Medical School
Clinical Development Issues for mAB-cytokines
Michael Derby, Ph.D.
Roche Palo Alto LLC
Overview of Drug-conjugation Monoclonal Antibodies
John Lambert, Ph.D.
ImmunoGen, Inc.
Analytical Issues for mAB-drug Conjugates
Surinder Kaur, Ph.D.
Genentech, Inc.
Preclinical Development Issues for Immunoconjugates
Jay Tibbitts, Ph.D., D.V.M
Genentech, Inc.
Analytical Issues for mAB-cytokine Conjugates
Speaker to be announced
Preclinical and Clinical Development of Recombinant Antibody-cytokine Fusion Proteins
Stephen D. Gillies, M.D.
EMD Lexigen Research Center